PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 4-32548A/USN	**FOR FURTHER ACTION**	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
International application No. PCT/IB 03/02794	International filing date *(day/month/year)* 17.06.2003	Priority date *(day/month/year)* 28.06.2002
International Patent Classification (IPC) or both national classification and IPC A61K31/506		
Applicant THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 5 sheets, including this cover sheet.

   ☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

   These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

   - I ☒ Basis of the opinion
   - II ☐ Priority
   - III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
   - IV ☐ Lack of unity of invention
   - V ☒ Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
   - VI ☐ Certain documents cited
   - VII ☐ Certain defects in the international application
   - VIII ☐ Certain observations on the international application

Date of submission of the demand	Date of completion of this report
15.12.2003	01.10.2004
Name and mailing address of the international preliminary examining authority: European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized Officer Hornich, E Telephone No. +49 89 2399-8721

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/IB 03/02794

I. Basis of the report

1. With regard to the **elements** of the international application *(Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17))*:

Description, Pages

1-11 as originally filed

Claims, Numbers

1-11 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

   These elements were available or furnished to this Authority in the following language: , which is:

   ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).

   ☐ the language of publication of the international application (under Rule 48.3(b)).

   ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

   ☐ contained in the international application in written form.

   ☐ filed together with the international application in computer readable form.

   ☐ furnished subsequently to this Authority in written form.

   ☐ furnished subsequently to this Authority in computer readable form.

   ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

   ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

   ☐ the description, pages:

   ☐ the claims, Nos.:

   ☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)).

   (Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

☐ the entire international application,

☒ claims Nos. 4-11 (with regard to industrial applicability only)

because:

☒ the said international application, or the said claims Nos. 4-11 (with regard to industrial applicability only) relate to the following subject matter which does not require an international preliminary examination (specify):

see separate sheet

☐ the description, claims or drawings *(indicate particular elements below)* or said claims Nos. are so unclear that no meaningful opinion could be formed *(specify)*:

☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.

☐ no international search report has been established for the said claims Nos.

2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

☐ the written form has not been furnished or does not comply with the Standard.

☐ the computer readable form has not been furnished or does not comply with the Standard.

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims	7 and 11
	No:	Claims	1-6, 8-10
Inventive step (IS)	Yes:	Claims	
	No:	Claims	1-11
Industrial applicability (IA)	Yes:	Claims	1-3
	No:	Claims	

2. Citations and explanations

see separate sheet

SECTION III

1. Claims 4-11 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(i) PCT).

SECTION V

2. *References*:

D1: WO 99 03854 A

D2: BOECKLIN F ET AL: 'Anti-fibrogenic effect of the tyrosine kinase inhibitor STI-571 on bone marrow fibrosis in chronic myeloid leukemia', BLOOD, vol. 96, no. 11 Part 1, 16 November 2000 (2000-11-16), page 734a, 42nd Annual Meeting of the American Society of Hematology; San Francisco, California, USA; December 01-05, 2000 ISSN: 0006-4971.

D3: M.H. BEERS, R. BERKOW: 'The Merck Manual of Diagnosis and Therapy' 1999 , MERCK RESEARCH LABORATORIES , WHITEHOUSE STATION, N.J.

3. *Novelty* **(Art. 33(2) PCT)**

3.1 **D1** discloses crystal forms of the methanesulfonic acid salt of imatinib, in particular the β-crystal form. The compound is useful for the treatment of non-malignant proliferative diseases, for instance *fibrosis* (p. 11, l. 4, 5). The compound may as well be used for treating or preventing *obliterative bronchiolitis* (p. 9, paragraph 3). According to **D3**, *bronchiolitis obliterans* is a disease involving the obstruction of bronchioles and alveolar ducts by fibrous granulation tissue.

D1 would thus ***destroy the novelty*** of the subject-matter of claims 1-6 and 8-10.

3.2 The novelty of the subject-matter of claims 1, 4-6, 8 and 9 would as well be ***anticipated*** by the disclosure of **D2.** The document teaches that '*STI-571 inhibits pathological fibrosis in liver and lung*'.

4. *Inventive Step* **(Art. 33(3) PCT)**

4.1 The subject-matter of claims 7 and 11 which would appear to be ***novel*** relates to *administration regimen and dosages* which would be considered a matter of routine optimization.
An inventive step could therefore ***not*** be ***acknowledged*** for the subject-matter of the aforementioned claims.

4.2 It is furthermore pointed to the following document which was not cited in the international search report.

D4: GISSLINGER, H. ET AL.: 'Imatinib Mesylate in Chronic Idiopathic Myelofibrosis, a Phase II Trial', BLOOD, vol. 100, no. 11, ABSTRACT NO.3161.

D4 reports on a phase II trial of imatinib mesylate in chronic idiopathic myelofibrosis. It is noted that treatment with *imatinib had to be withdrawn* in one patient *due to lung fibrosis*.

5. *Industrial Applicability* **(Art. 33(4) PCT)**

5.1 The requirements of industrial applicability would be fulfilled for the subject-matter of claims 1-3.

5.2 For the assessment of the present claims 4-11 on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.